Oncologic Inc.
Division of Aduro Biotech/Oncologic Inc.
www.oncologic.net
Latest From Oncologic Inc.
Deal Watch: Bristol, Janssen Keep The Heat High In Cancer Immunotherapy Deal-Making
Bristol signs a licensing deal around CytomX’s Probody technology platform and becomes the third firm to set up a combination trial with Incyte’s IDO1 inhibitor. Janssen licenses novel immunotherapy candidates for prostate cancer from Aduro; Oncothyreon and Celldex arrange a combo trial in breast and ovarian cancer.
Start-Up Previews (9/02)
Oncologic Inc.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- Cancer
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Aduro Biotech
- Senior Management
-
Stephen T Isaacs, Pres. & CEO
Winston Salser, Chmn. - Contact Info
-
Oncologic Inc.
Phone: (510) 222-3501
3065 Richmond Pkwy.
Ste. 117
Richmond, CA 94806
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice